Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
MetadataShow full item record
Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed de novo small cell lung cancer in early phase trials. Here, we report a case of transformed EGFR-mutant SCLC treated with nivolumab with no benefit.
Carcinoma, Non-Small-Cell Lung
Cell Transformation, Neoplastic
Antineoplastic Combined Chemotherapy Protocols
Drug Resistance, Neoplasm
Small Cell Lung Carcinoma
Positron Emission Tomography Computed Tomography
License start date
Lung cancer (Amsterdam, Netherlands), 2017, 111 pp. 65 - 68